Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323353621> ?p ?o ?g. }
- W4323353621 endingPage "346" @default.
- W4323353621 startingPage "335" @default.
- W4323353621 abstract "COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2.OnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and the UK with a laboratory-confirmed diagnosis of COVID-19 and a history of solid or haematological malignancy, either active or in remission, followed up from COVID-19 diagnosis until death. We evaluated the prevalence of COVID-19 sequelae in patients who survived COVID-19 and underwent a formal clinical reassessment, categorising infection according to the date of diagnosis as the omicron (B.1.1.529) phase from Dec 15, 2021, to Jan 31, 2022; the alpha (B.1.1.7)-delta (B.1.617.2) phase from Dec 1, 2020, to Dec 14, 2021; and the pre-vaccination phase from Feb 27 to Nov 30, 2020. The prevalence of overall COVID-19 sequelae was compared according to SARS-CoV-2 immunisation status and in relation to post-COVID-19 survival and resumption of systemic anticancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974.At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24-68) from COVID-19 diagnosis, were included (964 [50·7%] of 1902 patients with sex data were female and 938 [49·3%] were male). Overall, 317 (16·6%; 95% CI 14·8-18·5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19·1%; 95% CI 16·4-22·0] of 1000 patients). The prevalence was similar in the alpha-delta phase (110 [16·8%; 13·8-20·3] of 653 patients, p=0·24), but significantly lower in the omicron phase (16 [6·2%; 3·5-10·2] of 256 patients, p<0·0001). In the alpha-delta phase, 84 (18·3%; 95% CI 14·6-22·7) of 458 unvaccinated patients and three (9·4%; 1·9-27·3) of 32 unvaccinated patients in the omicron phase had sequelae. Patients who received a booster and those who received two vaccine doses had a significantly lower prevalence of overall COVID-19 sequelae than unvaccinated or partially vaccinated patients (ten [7·4%; 95% CI 3·5-13·5] of 136 boosted patients, 18 [9·8%; 5·8-15·5] of 183 patients who had two vaccine doses vs 277 [18·5%; 16·5-20·9] of 1489 unvaccinated patients, p=0·0001), respiratory sequelae (six [4·4%; 1·6-9·6], 11 [6·0%; 3·0-10·7] vs 148 [9·9%; 8·4-11·6], p=0·030), and prolonged fatigue (three [2·2%; 0·1-6·4], ten [5·4%; 2·6-10·0] vs 115 [7·7%; 6·3-9·3], p=0·037).Unvaccinated patients with cancer remain highly vulnerable to COVID-19 sequelae irrespective of viral strain. This study confirms the role of previous SARS-CoV-2 immunisation as an effective measure to protect patients from COVID-19 sequelae, disruption of therapy, and ensuing mortality.UK National Institute for Health and Care Research Imperial Biomedical Research Centre and the Cancer Treatment and Research Trust." @default.
- W4323353621 created "2023-03-08" @default.
- W4323353621 creator A5001248487 @default.
- W4323353621 creator A5001860526 @default.
- W4323353621 creator A5002745641 @default.
- W4323353621 creator A5004582424 @default.
- W4323353621 creator A5006436854 @default.
- W4323353621 creator A5008719596 @default.
- W4323353621 creator A5008733981 @default.
- W4323353621 creator A5009737345 @default.
- W4323353621 creator A5012020928 @default.
- W4323353621 creator A5013672715 @default.
- W4323353621 creator A5013768705 @default.
- W4323353621 creator A5015509025 @default.
- W4323353621 creator A5016458469 @default.
- W4323353621 creator A5017243208 @default.
- W4323353621 creator A5017742868 @default.
- W4323353621 creator A5018109573 @default.
- W4323353621 creator A5019053015 @default.
- W4323353621 creator A5020078965 @default.
- W4323353621 creator A5020287494 @default.
- W4323353621 creator A5020344479 @default.
- W4323353621 creator A5020684039 @default.
- W4323353621 creator A5020920722 @default.
- W4323353621 creator A5020991260 @default.
- W4323353621 creator A5022151942 @default.
- W4323353621 creator A5022223456 @default.
- W4323353621 creator A5023104932 @default.
- W4323353621 creator A5023635260 @default.
- W4323353621 creator A5024226148 @default.
- W4323353621 creator A5025464974 @default.
- W4323353621 creator A5025486771 @default.
- W4323353621 creator A5026082633 @default.
- W4323353621 creator A5026537362 @default.
- W4323353621 creator A5026708766 @default.
- W4323353621 creator A5027094790 @default.
- W4323353621 creator A5027231412 @default.
- W4323353621 creator A5027700319 @default.
- W4323353621 creator A5029108741 @default.
- W4323353621 creator A5030010530 @default.
- W4323353621 creator A5031403658 @default.
- W4323353621 creator A5031414207 @default.
- W4323353621 creator A5031666050 @default.
- W4323353621 creator A5032637708 @default.
- W4323353621 creator A5033376998 @default.
- W4323353621 creator A5034412136 @default.
- W4323353621 creator A5034946806 @default.
- W4323353621 creator A5035175323 @default.
- W4323353621 creator A5035799376 @default.
- W4323353621 creator A5036133691 @default.
- W4323353621 creator A5037339388 @default.
- W4323353621 creator A5037357574 @default.
- W4323353621 creator A5038556220 @default.
- W4323353621 creator A5038655854 @default.
- W4323353621 creator A5039375708 @default.
- W4323353621 creator A5040629138 @default.
- W4323353621 creator A5041745367 @default.
- W4323353621 creator A5041957010 @default.
- W4323353621 creator A5041977580 @default.
- W4323353621 creator A5044102832 @default.
- W4323353621 creator A5044256192 @default.
- W4323353621 creator A5044624546 @default.
- W4323353621 creator A5045454738 @default.
- W4323353621 creator A5046687314 @default.
- W4323353621 creator A5046721152 @default.
- W4323353621 creator A5047644166 @default.
- W4323353621 creator A5049914998 @default.
- W4323353621 creator A5050187820 @default.
- W4323353621 creator A5050278529 @default.
- W4323353621 creator A5051093023 @default.
- W4323353621 creator A5051429954 @default.
- W4323353621 creator A5051894396 @default.
- W4323353621 creator A5052090354 @default.
- W4323353621 creator A5053521368 @default.
- W4323353621 creator A5053524419 @default.
- W4323353621 creator A5055028563 @default.
- W4323353621 creator A5055686786 @default.
- W4323353621 creator A5056412323 @default.
- W4323353621 creator A5056871445 @default.
- W4323353621 creator A5058760175 @default.
- W4323353621 creator A5059519339 @default.
- W4323353621 creator A5060146720 @default.
- W4323353621 creator A5060954139 @default.
- W4323353621 creator A5061095811 @default.
- W4323353621 creator A5061596789 @default.
- W4323353621 creator A5061758533 @default.
- W4323353621 creator A5062065961 @default.
- W4323353621 creator A5062940651 @default.
- W4323353621 creator A5064721777 @default.
- W4323353621 creator A5064760773 @default.
- W4323353621 creator A5065498107 @default.
- W4323353621 creator A5065803904 @default.
- W4323353621 creator A5065961744 @default.
- W4323353621 creator A5066059934 @default.
- W4323353621 creator A5066742157 @default.
- W4323353621 creator A5069756772 @default.
- W4323353621 creator A5071404308 @default.
- W4323353621 creator A5071929183 @default.